LYHLT:SW:SW-Multi Units Luxembourg - Amundi STOXX Europe 600 Healthcare UCITS ETF Acc EUR (EUR)

ETF | Others |

Last Closing

USD 153.42

Change

0.00 (0.00)%

Market Cap

USD 0.83B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.02 (-0.17%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.05 (-0.22%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.19 (+0.72%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-19.00 (-0.36%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

N/A

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-3.00 (-0.14%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

-0.10 (-0.13%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

-0.68 (-0.61%)

USD 130,595.12B

ETFs Containing LYHLT:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.14% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.14% 62% D 64% D
Trailing 12 Months  
Capital Gain 17.40% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.40% 65% D 67% D+
Trailing 5 Years  
Capital Gain 46.95% 72% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.95% 72% C 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.09% 72% C 72% C
Dividend Return 8.09% 72% C 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.94% 51% F 57% F
Risk Adjusted Return 101.89% 100% F 99% N/A
Market Capitalization 0.83B 68% D+ 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike